Subgroup variations in effectiveness of femoropopliteal sirolimus versus paclitaxel-coated balloon angioplasty: post hoc results of the randomised SIRONA trial.

Authors

Ulf Teichgräber, Maja Ingwersen, Thomas Lehmann, Stephanie Platzer, Ina Kunstmann, Sabine Steiner, Andrej Schmidt, Tim Wittig, Thomas Zeller, Marcus Thieme, Hans Krankenberg, Martin Werner, Marianne Brodmann, Nasser Malyar, Stefan Müller-Hülsbeck, Luca de Paoli, Oliver Schlager, Martin Austermann, Gunnar Tepe, Christian Erbel, Wulf Ito, Rainer Waßmer, Lars Maiwald, René Aschenbach, Christian Wissgott, Martin Andrassy, Florian Wolf, Ulrich Beschorner, Maciej Pech, Konstantinos Katsanos, Dierk Scheinert

Published in

CVIR endovascular. Volume 9. Issue 1. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

The randomised SIRONA trial showed that sirolimus-coated balloon (SCB) angioplasty was non-inferior to paclitaxel-coated balloon angioplasty (PCB) regarding femoropopliteal primary patency. There was no difference in clinically driven target lesion revascularisation (cdTLR) rates between the treatment groups. This post-hoc analysis aimed to assess whether the overall results were consistent across different subgroups and selected post-baseline factors.
Primary patency at 12 months was assessed using duplex ultrasound and adjudicated by a core laboratory for 203 and 199 participants in the SCB and PCB groups, respectively (available-case intention-to-treat analysis). Data on 12-month cdTLR were available for 238 and 244 participants in the SCB and PCB groups, respectively. Odds ratios (ORs) for primary patency and hazard ratios (HRs) for cdTLR after SCB compared to PCB in non-pre-specified subgroups were assessed using generalised linear mixed models to control for centre effects, and Cox proportional hazards models, respectively.
Primary patency and cdTLR were generally consistent across the analysed subgroups. Two nominal interaction signals were observed. For cdTLR, a nominal interaction with age was identified (interaction p = 0.047); among participants older than 70 years, the estimated hazard ratio favoured SCB (HR 0.52, 95% CI 0.16-1.71). For primary patency, treatment effects differed according to residual diameter stenosis (interaction p = 0.022); the estimated treatment effect favoured SCB in participants with residual diameter stenosis > 30% (OR 1.67, 95% CI 0.76-3.65). No other interactions between treatment and subgroup or post-baseline factors were observed.
The effectiveness of SCB compared to PCB was similar and mainly consistent among subgroups. The evaluation should be considered exploratory.
ClinicalTrials.gov, NCT04475783. Registered 17 July 2020, https://clinicaltrials.gov/study/NCT4475783 .

PMID:
42576093
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.